| pubmed-article:3123673 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C0002874 | lld:lifeskim |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C0021080 | lld:lifeskim |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C0018026 | lld:lifeskim |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C0021079 | lld:lifeskim |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C0205265 | lld:lifeskim |
| pubmed-article:3123673 | lifeskim:mentions | umls-concept:C1555582 | lld:lifeskim |
| pubmed-article:3123673 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:3123673 | pubmed:dateCreated | 1988-3-2 | lld:pubmed |
| pubmed-article:3123673 | pubmed:abstractText | Three patients who received antithymocyte globulin therapy for severe aplastic anemia due to gold therapy are described. In 2 patients the hemoglobin, white blood cell count and neutrophils were normal and platelet counts exceeded 100 X 10(9)/1 more than 2 years after treatment. The 3rd patient did not respond to antithymocyte globulin or to cyclosporine therapy; subsequent allogeneic bone marrow transplantation resulted in satisfactory engraftment at 12 months. In all 3 patients the arthritis was improved after the episode of marrow aplasia and its treatment. Including these 3 patients, 12 reported patients with severe aplastic anemia due to gold have now been treated with antithymocyte globulin; 8 have shown significant improvement. These results are better than those reported for any other treatment. Antithymocyte globulin may be optimal initial treatment for this serious disorder. | lld:pubmed |
| pubmed-article:3123673 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3123673 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123673 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3123673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3123673 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3123673 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:3123673 | pubmed:issn | 0315-162X | lld:pubmed |
| pubmed-article:3123673 | pubmed:author | pubmed-author:MantM JMJ | lld:pubmed |
| pubmed-article:3123673 | pubmed:author | pubmed-author:DavisPP | lld:pubmed |
| pubmed-article:3123673 | pubmed:author | pubmed-author:RussellA SAS | lld:pubmed |
| pubmed-article:3123673 | pubmed:author | pubmed-author:PercyJ SJS | lld:pubmed |
| pubmed-article:3123673 | pubmed:author | pubmed-author:MessnerH AHA | lld:pubmed |
| pubmed-article:3123673 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3123673 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:3123673 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3123673 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3123673 | pubmed:pagination | 1026-9 | lld:pubmed |
| pubmed-article:3123673 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:meshHeading | pubmed-meshheading:3123673-... | lld:pubmed |
| pubmed-article:3123673 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3123673 | pubmed:articleTitle | Immunosuppression as initial treatment for gold induced aplastic anemia. | lld:pubmed |
| pubmed-article:3123673 | pubmed:affiliation | Department of Medicine, University of Alberta Hospital, Edmonton, Canada. | lld:pubmed |
| pubmed-article:3123673 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3123673 | pubmed:publicationType | Case Reports | lld:pubmed |
